IL147731A0 - Peptide pharmaceutical formulations - Google Patents

Peptide pharmaceutical formulations

Info

Publication number
IL147731A0
IL147731A0 IL14773101A IL14773101A IL147731A0 IL 147731 A0 IL147731 A0 IL 147731A0 IL 14773101 A IL14773101 A IL 14773101A IL 14773101 A IL14773101 A IL 14773101A IL 147731 A0 IL147731 A0 IL 147731A0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulations
peptide pharmaceutical
peptide
formulations
pharmaceutical
Prior art date
Application number
IL14773101A
Other languages
English (en)
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Priority claimed from PCT/US2001/015872 external-priority patent/WO2001087322A2/fr
Publication of IL147731A0 publication Critical patent/IL147731A0/xx

Links

IL14773101A 2000-05-19 2001-05-17 Peptide pharmaceutical formulations IL147731A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20526200P 2000-05-19 2000-05-19
PCT/US2001/015872 WO2001087322A2 (fr) 2000-05-17 2001-05-17 Preparations pharmaceutiques peptidiques

Publications (1)

Publication Number Publication Date
IL147731A0 true IL147731A0 (en) 2002-08-14

Family

ID=22761491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14773101A IL147731A0 (en) 2000-05-19 2001-05-17 Peptide pharmaceutical formulations

Country Status (4)

Country Link
EP (1) EP1301200A2 (fr)
JP (1) JP2004513069A (fr)
AU (1) AU785444B2 (fr)
IL (1) IL147731A0 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506786B1 (fr) 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Compositions medicinales contenant de la ghreline
KR101149454B1 (ko) 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
US20200289621A1 (en) 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3075984C (fr) 2017-09-22 2024-10-01 Asahi Kasei Pharma Corporation Composition pharmaceutique liquide contenant de la teriparatide presentant d'excellentes proprietes pharmacocinetiques et/ou d'innocuite
ES3017234T3 (en) * 2019-09-25 2025-05-12 Lumosa Therapeutics Co Ltd Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性grf経鼻投与製剤
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
WO1999047160A1 (fr) * 1998-03-13 1999-09-23 Novo Nordisk A/S Solutions peptidiques aqueuses stabilisees
EP1064934A1 (fr) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. Compositions lyophilisées contenant du GRF

Also Published As

Publication number Publication date
AU7483901A (en) 2001-11-26
EP1301200A2 (fr) 2003-04-16
JP2004513069A (ja) 2004-04-30
AU785444B2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
GB0319041D0 (en) Pharmaceutical Formulations
GB0001621D0 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB0105560D0 (en) Pharmaceutical formulations
EP1173216A4 (fr) Formulations pharmaceutiques
IL147731A0 (en) Peptide pharmaceutical formulations
AU2001296389A1 (en) Stable peptide formulations
GB0014851D0 (en) Novel pharmaceutical formulation
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
IL135442A0 (en) Peptides and pharmaceutical compositions comprising them
GB0124455D0 (en) Pharmaceutical formulations
GB0021487D0 (en) Pharmaceutical
GB0014869D0 (en) Novel pharmaceutical formulation